^
    25d
    ADAM and ADAMTS Proteases in Breast Cancer: Molecular Mechanisms and Therapeutic Implications. (PubMed, Clin Breast Cancer)
    Multiple therapeutic modalities have been validated, including small-molecule inhibitors (INCB7839, INCB3619, GI254023X) that suppress ligand shedding and enhance trastuzumab efficacy, RNA interference (siRNA/miRNA) for targeted gene silencing, and engineered nanocarrier drug delivery platforms that overcome therapeutic resistance. The epigenetic regulation, post-translational modifications, and diagnostic advancements, such as SERS-based serum profiling, further underscore their value as biomarkers and druggable targets. Collectively, ADAM/ADAMTS-centered interventions represent a promising direction for precision oncology and therapeutic targets for improving clinical outcomes in breast cancer.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TNFA (Tumor Necrosis Factor-Alpha) • ADAM17 (ADAM Metallopeptidase Domain 17) • ADAM10 (ADAM Metallopeptidase Domain 10)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • aderbasib (INCB7839)
    12ms
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=13, Completed, Pediatric Brain Tumor Consortium | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Dec 2024
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • ADAM10 (ADAM Metallopeptidase Domain 10)
    |
    aderbasib (INCB7839)
    1year
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • ADAM10 (ADAM Metallopeptidase Domain 10)
    |
    aderbasib (INCB7839)
    over2years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Pediatric Brain Tumor Consortium | Recruiting --> Active, not recruiting | N=28 --> 13
    Enrollment closed • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)
    3years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=28, Recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)
    over3years
    Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. (PubMed, J Exp Clin Cancer Res)
    Our study shows that CRC resistance to EGFR inhibitors results primarily from the inability of the inhibitors to downregulate their target and that a PEPD-based combination treatment overcomes the resistance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ADAM17 (ADAM Metallopeptidase Domain 17) • ADAM10 (ADAM Metallopeptidase Domain 10)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • EGFR overexpression • PIK3CA expression • PIK3CA overexpression • KRAS expression
    |
    Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • aderbasib (INCB7839)
    4years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=28, Recruiting, Pediatric Brain Tumor Consortium | Trial primary completion date: Mar 2022 --> Dec 2022
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)
    over4years
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=28, Recruiting, Pediatric Brain Tumor Consortium | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    aderbasib (INCB7839)